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Abstract
Background: Concurrent with efforts to establish national and regional biorepositories in Africa is widespread
endorsement of ethics committees as stewards of the interests of individual donors and their communities. To
date, ethics training programs for IRB members in Botswana have focused on ethical principles and international
guidelines rather than on the ethical dimensions of specific medical technologies and research methodologies.
Little is known about the knowledge and concerns of current and prospective IRB members in Botswana with
respect to export, reuse, storage, and benefit-sharing of biospecimens.
Methods: This qualitative study examined perspectives of IRB members in Botswana about the collection and
use of biospecimens in research. Forty-one IRB members representing five committees in Botswana
participated in discussions groups in March 2013. Transcriptions of audiotapes and field notes were analyzed
to identify issues of concern that might be alleviated through education and capacity-building, and areas that
required ongoing discussion or additional regulatory guidance.
Results: Areas of concern included lack of understanding among patients and providers about the use of
biospecimens in clinical care and research; reuse of biospecimens, particularly issues of consent, ownership
and decision-making; export of specimens and loss of control over reuse and potential benefits; and felt need
for regulatory guidance and IRB-member training. Local belief systems about bodily integrity and strong
national identity in the construct of benefits may be at odds with initiatives that involve foreign
biorepositories or consider such collections to be global public goods.
Conclusion: Education is needed to strengthen IRB-member capacity to review and monitor protocols
calling for the collection and use of biospecimens, guided by clear national policy on priority-setting,
partnerships, review, and oversight. Engagement with local stakeholders is needed to harmonize
fundamentally different ways of understanding the human body and community identity with the aims of
contemporary biomedicine.
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Background
Advances in pharmacogenetics and genomics research
and their potential to yield public health benefits have
contributed to the growing use of human biological speci-
mens (HBS) in research and the establishment, mainly in
developed countries, of large-scale biorepositories. Sam-
ples from African populations have been included in
several public genome reference collections, among them
the International HapMap Project, The 1000 Genomes
Project, and the Malaria Genomic Epidemiology Network
[1–3]. In the past decade, several African biorepositories
have been established, including The Gambia National
DNA Bank, the African Institute of Biomedical Science
and Technology (Zimbabwe) and the biobank at the
University of Kwazulu-Natal’s African Centre for Health
and Population Studies in South Africa [4–6].
Recently, international efforts to establish a number of re-
gional pan-African biorepositories have gained momentum,
largely under the aegis of the Human Heredity and Health
in Africa Initiative (H3Africa) [7]. Four pilot regional
biobanks are in development- two in South Africa and one
each in Nigeria and Uganda. The H3Africa Initiative cen-
ters on a ‘hub-and-spoke’ model, with biobanks serving as
regional biorepositories of specimens collected as part of
research initiatives situated in universities and centers
across Africa [8]. It is anticipated that all H3Africa research
projects will begin to send a portion or all of their samples
to one of these biobanks starting in 2014 [9].
Biobanking introduces highly complex ethical chal-
lenges, particularly in Africa where limited access tore-
search ethics education and familiarity with drug/treatment
development may make it difficult for research participants
to understand the risks and the potential benefits associated
with genetic research and where regulatory guidance on
collection, use, export, ownership and storage of biospeci-
mens is scant [10–12]. Ethics reviewers may lack sufficient
understanding about these technologies or have limited
access to accurate information on which to base their deci-
sions. “Northern” conceptualizations of self, human origins,
risks and potential benefits have shaped approaches to con-
sent, specimen collection, ownership and information shar-
ing — approaches that may be at odds with local meaning-
making and therefore of limited value in determining what
constitutes ethical practice in these communities [13].
Recent work by Staunton and Moodley identified five
studies in the literature that have examined community
perspectives on the storage and reuse of biospecimens in
countries in Sub-Saharan Africa [12]. Less research has
been done to date to gauge the knowledge and perspectives
of local ethics committee members who have an essential
role to play in protecting stakeholder interests. IRB mem-
bers may require more information about the science and
ethical use of biospecimens in research as well as better
policy guidance at a national level if they are to strike the
right balance between ensuring safeguards for subjects and
their communities on the one hand and facilitating research
with potential public health benefits on the other. As efforts
to establish biobanks across the African continent expand,
due consideration must be given to the extent to which
ethics committees have the knowledge to serve as ethical
gatekeepers, particularly in communities where local un-
derstanding of biomedicine may be rudimentary or at odds
with cultural meanings traditionally ascribed to biological
phenomena.
Botswana has attracted global attention over the past
three decades as a hub for behavioral, epidemiological,
and clinical research. A number of foreign academic re-
search universities and NGOs have established study cen-
ters in Botswana, including Baylor International Pediatric
AIDS, Botswana Harvard AIDS Institute Partnership,
otswana-UPenn Partnership, BOTUSA Project, and I-
TECH Botswana [14–18]. The University of Botswana
opened the country’s first medical school and school of
public health in 2009 and has a commitment to advance
research and graduate studies as part of its current stra-
tegic plan [19]. A number of studies examining genetic at-
tributes of particular sub-populations in Botswana have
already begun [20, 21] and the creation of a biorepository
at the University of Botswana with the eventual public
release of data for future research activities is planned as
part of the H3Africa initiative [22].
The Botswana Anthropological Research Act of 1967
provides the basis for research regulation [23]. In 1984, a
Health Research Unit (HRU) was created within the Minis-
try of Health (MoH) and a Health Research and Develop-
ment Committee (HRDC) established to review, approve,
and oversee all health-related research. An Institutional
Review Board (IRB) has been in operation at the University
of Botswana since 2004; it is responsible for the review and
approval of all undergraduate and masters-level research
permits and intramural faculty research. It is also tasked
with the preliminary review and referral of all health-
related PhD and international research to the HRDC for
final approval. IRBs have also been in operation for some
time at large referral hospitals in Gaborone, Francistown,
and Maun. In 2010, the MoH launched a multi-year
endeavor to create a country-wide system of local ethics
committees to meet the growing demand for ethics review
and the expansion of research activities to small communi-
ties outside the capital city. Frameworks now exist in a
number of the district hospitals for ‘local’ IRBs to provide
feedback to the HRDC on the feasibility of projects pro-
posed for their facilities, although most lack infrastructure
and research expertise (Kasule M 2014, personal communi-
cation). New ethics committees have also been established
in various tertiary academic institutions throughout the
country, but these are limited in their scope of authority to
the review of research proposals by students at the masters
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level and below. Reviews conducted by this emergent
‘system’ of IRBs are submitted as recommendations to the
HRDC, which operates as the national review body for
Botswana and remains responsible for final review and
monitoring of all health research in the country.
The HRDC is guided by principles articulated in the
Declaration of Helsinki, and the Council for International
Organizations of Medical Sciences’ International Ethical
Guidelines for Biomedical Research involving Human
Subjects [24, 25]. Until recently, regulatory guidance on
HBS existed only for clinical trials relating to drug applica-
tions [26]. In 2011, the Ministry of Health issued Standard
Operating Procedures intended to guide the structure and
operation of the HRDC and the review of research proto-
cols involving human subjects [27]. A National Health
Research Bill remains under review at the parliamentary
level.
To date, ethics training programs for IRB members in
Botswana have focused on ethical principles and inter-
national guidelines rather than on ethical dimensions of
specific medical technologies and research methodologies.
Little is known about the knowledge, concerns, and training
needs of IRB members in Botswana with respect to the use
of biospecimens in biomedical research.
Methods
Members of the HRDC and all IRBs in Botswana at the
time of the study were invited by letter with follow-up
phone and email reminders to participate in one of several
focus groups to be held at various locations in Botswana in
March 2013. A total of 41 IRB members drawn from five
different committees participated, a sample representing a
majority of those members serving on committees tasked
with review of protocols involving HBS. Sessions were
designed to elicit IRB-member perceptions of common
attitudes and beliefs of Batswana (the people of Botswana)
towards the collection and use of HBS for research and to
gauge member knowledge and attitudes about these issues.
Additionally, the research team was interested in IRB-
member awareness of existing national regulation regarding
the collection and use of HBS, their confidence in its
adequacy to guide review, and their perceived need for
additional training.
Focus groups took place in Gaborone (two groups of 17
and six participants, respectively) and Francistown (one
group of 10 participants), both urban centers in which
biomedical research activity has to date been concentrated.
One discussion group (eight participants) took place in
Mahalapye, a major town to the northeast of Gaborone
where the new District Hospital has recently appointed its
first IRB. Approximately 70 % of the participants were
female. All had received some training in research ethics,
but none had received training specific to biospecimens,
genetic or genome-based research, or bio-repositories. A
number of the members from the HRDC and the Univer-
sity of Botswana were researchers and health professionals
familiar with biomedical science. The remaining three com-
mittees represented were relatively new, tasked with ‘local’
review of protocols that will be situated in their hospitals
and with evaluating their suitability given hospital capacity
and local cultural norms and practices. Members of these
committees tend to have received less training in ethics
compared to their urban counterparts and are less familiar
with health research in general. Ethical issues concerning
the collection and use of HBS has not been a topic of focus
in ethics training programs to date.
Each focus group discussion was guided by a study
script. Study questions were chosen with the intention
to stimulate a free-flowing conversation in English (the
official language of Botswana) to explore IRB members’
own views on the collection and use of biospecimens, as
well as what they perceived to be the views of local
communities.
Four central questions guided each discussion group:
1. From your perspective, how do the peoples of
Botswana feel about the collection of biospecimens?
2. From your perspective, how do the peoples of
Botswana feel about biospecimens being kept or
stored after the original research has been
completed?
3. As an IRB reviewer or someone interested in ethics,
what are your greatest concerns about the storage
and reuse of biospecimens?
4. Should there be any constraints or conditions placed
on the future use of stored biospecimens after the
original research is over?
All participants were briefed about the study, given oppor-
tunity to ask questions, and were asked for their written
consent prior to the start of each session. Focus groups
lasted approximately ninety minutes and were audiotaped.
Extensive handwritten notes, audio transcripts and obser-
vations by the project team over the course of the project
formed the basis for categorizing participant responses
and identifying themes. The aim was to identify issues of
greatest concern to reviewers in Botswana, aspects of
those concerns that might be alleviated through education
and capacity-building, and areas that might be addressed
through ongoing discussion between stakeholders and the
international research community or the development of
national research guidelines. To minimize the likelihood
of misinterpretation, members of the study team solicited
feedback on transcriptions of particular passages to con-
firm or reconsider their understanding of discussant
views.
An informal training session about genetic and genomic
research was offered at the end of each discussion group.
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These sessions, intended as a capacity-building effort,
were not audiotaped nor were discussions that took place
during them considered study data.
The project was reviewed and approved prior to its
implementation by the Institutional Review Boards at
Rutgers University, the University of Botswana and the
University of Pennsylvania, as well as the Health Re-
search and Development Committee at the Botswana
Ministry of Health.
For the purposes of the study, a number of words
whose conceptual meanings did not directly translate
into English were left in Setswana, the recognized local
language of Botswana. Batswana is the collective noun
used to describe the people of Botswana. Go rupa and
bogwera, once terms in Setswana (the local language of
Botswana) used to describe traditional initiation cere-
monies for adolescent boys, is now used by the Botswana
MoH to refer to medical male circumcision. Muti is the
Setswana term used to refer to objects of witchcraft. In
describing the ethics system in Botswana, the study used
terms commonly used in that country. Ethics research
committees in Botswana are referred to as ‘IRBs’ and its
members as ‘IRB members’. The IRB at the Ministry of
Health is called the Health Research and Development
Committee (HRDC).
Results
Cultural traditions, norms and beliefs
A significant amount of time in each focus group was
devoted to topics having to do with belief systems and
cultural norms that were perceived to influence how the
collection of biospecimens would be viewed by individ-
uals and communities in Botswana. All four groups refer-
enced Botswana’s current national safe male-circumcision
(SMC) campaign to illustrate how cultural meanings can
affect local understanding of a medical procedure. Until
the mid-20th century when medical missionaries actively
discouraged the practice in Botswana, circumcision was
part of a month-long rite-of-passage for adolescent boys
that taught traditions, values, and ways in which men
should relate to women [28]. Meanings that were once
attached to circumcision remain, reinforced by the
campaign’s use of the Setswana term for the traditional
initiation, go rupa or bogwera, as the term for the medical
procedure itself.
“When [the campaign] started, [health workers] took
their foreskins and just threw them away. Local people
were concerned because this is not a tissue. This has
meaning. There was a rumor that the foreskins were
being sold to traditional doctors. They started thinking
that maybe this circumcision is not what they thought
it would be.”
Study participants also observed many Batswana are
concerned that foreskins removed as part of this campaign
are being sold for other people’s use. Many people,
particularly those with less education and those from
remote areas of the country, still believe in witchcraft and
fear that body parts, including blood and samples that are
collected by health workers, will be stolen or sold to make
powerful magic (muti) that can harm or bring benefit to
others.
Discussions of religious beliefs were common to all four
groups. Belief that “God has his own way of healing” was
seen as discouraging patient utilization of medical services
in general, and by extension, of experimental efforts to
treat and cure disease. As one discussant characterized a
common local sentiment:
“Why should I allow a medical person to collect a
sample from me? If I am sick, for example, if I have
cancer; God has his way of healing cancer. Why would
I just allow a person who gets his wisdom from God to
go and test it? Nature will take its course; it will heal
in time if one believes in God.”
The cultural significance of bodily integrity was seen to
stem from the belief that one must return to one’s Maker
‘whole’ and from the importance placed on being able to
account for one’s ‘parts’ at the moment of death. One IRB
member, describing the case of a young Motswana woman
who had had a mastectomy while living outside of
Botswana, characterized local fears about loss of bodily
integrity in this manner:
“If these [stored] specimens are out there somewhere in
the developed world – far out there- just as I am
about to die, can these specimens come back because I
want to go to my grave whole? Not to leave part of it
over there, overseas? How do these specimens come
back? I will not have a peaceful death because I am
worried that I am facing death without all my
specimens. A breast is somewhere.”
Lack of trust
At odds with what IRB members described as Batswana’s
‘tendency to trust’ was the consensus across groups that
there was a general lack of trust in research and, by
extension, in researchers themselves. Foreign researchers
were viewed with greater distrust than local researchers:
“If you are a foreign team coming from outside and
going to the rural areas, there may be suspicion.
Even if you are from Botswana and you come with a
team – let’s say you are coming from Gaborone to a
rural area- they will always suspect that you are
going to take something and that you are doing it for
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something. But if you were from a foreign country, I
think it will be even worse.”
One group discussed at length what it perceived to be
the general erosion of trust in clinicians as a direct result
of medical research activity in Botswana. What was once
trust in the medical doctor to care for the people’s needs
has now been replaced by skepticism as to the under-
lying motives of the health care team. Referring to the
current SMC campaign as an illustration of the problem,
one IRB member who was a physician offered:
“I think that [early on] they saw the [actual] process of
circumcision as a medical component – as separate
from the rest of the circumcision initiation. They never
asked what we were going to do. I think they were
confident that we were doing exactly what we said we
were going to do… Since research arrived in the
country, most people are wary of research, suddenly
these issues take on a different complexion. These tests
are often not used for the person’s own care. So they
don’t know who will see the results or how [specimens]
will be used.”
Misunderstanding of the role of biospecimens in clinical
and research settings
Considerable discussion took place in all sessions about the
general lack of knowledge in the population about biomedi-
cine, both in clinical and research settings. Participants
observed that Batswana on the whole associate the giving
of a specimen with clinical care and perceive that in doing
so they are contributing to their own well-being. Sick
patients come for treatment; physicians draw blood or take
a urine sample which goes to the ‘lab’ either for the doctor
to use in diagnosing the cause of illness or as an ingredient
for a treatment that the nurse or doctor prepares for them
in the form of a pill, an injection, or a salve. The patient
returns home and in due course feels better. The scenario
suggests that often patients associate specimens with treat-
ment, that they believe that their specimens are “used up”
in the preparation of that treatment (effectively returning
one’s specimen in another form), and that the giving of
specimens results in personal benefit. To date, most
biomedical research and specimen collection in Botswana
has taken place in hospital settings or in association with
patient care. Research subjects give specimens because
they expect a cure.
“You know, most Batswana, they expect to get results
after you’ve collected a specimen, But now with
research, if you take a specimen, you are not going to
give any results. Is that right? [Researchers] go to
families and collect blood specimens. And the results
are not revealed to the people. They were advised to go
to the hospital to get tested to know their HIV status.
So you know from their perspective, they feel cheated.
They sometimes feel cheated when it is put that way.”
Some patients believe that the collection of certain types
of specimens, especially spinal fluid, actually worsens health
and may hasten death in sick patients. Spinal taps, invari-
ably performed in very sick patients, were reported to be
broadly perceived as deadly. In instances of amputation or
extraction, it was not uncommon for patients to ask that
the limb or tooth be returned to them for ritual disposal.
Several IRB members observed that most Batswana
were unaware that samples collected as part of clinical
care were generally kept by the medical facility. As one
IRB member who was medical staff commented:
“I think mostly they don’t know that they are being
kept. If they knew…they will think that persons are
using their specimens to do something else which they
didn’t agree to. Mostly they don’t know. They think
that their specimen was taken and was used.”
Reuse of biospecimens
Questions regarding reuse elicited broadly diverse re-
sponses from participants on issues relating to consent,
privacy and confidentiality, criteria for reuse, competing
research interests, and benefits. A number of IRB mem-
bers offered that Batswana are likely to be very concerned
over specimens being re-used for purposes for which they
have not given explicit consent. Several participants felt
that a blanket consent for reuse obtained at the time of
collection might be acceptable, although they were con-
cerned that research subjects would not fully appreciate
the risks and potential benefits associated with such a
choice. There was particular concern voiced about the
legitimacy of consents obtained from Botswana’s most vul-
nerable populations, such as the San people of the Kalahari,
who may not have fully understood the information on
which they were asked to base their decisions.
“If they are going to take research samples and store
them for a long time and then use them for studies
that are not disclosed to the individuals, then those
persons do not have autonomy over what is going to be
don. The researcher needs to at least say something
like ‘I am going to use this in the future for HIV
research’, and then if the researcher were to [want to]
use it for some other purposes, it would not be
permitted without permission… I do not think there
should be blanket consent, particularly for research
that relates specifically to them [the participants].”
Consent for each new use was the predominant pref-
erence among discussants, although there were mixed
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opinions about the source and nature of such consent.
A number of IRB members felt that even when research
subjects could give meaningful consent to reuse at the
time of collection, requests for reuse should still be
reviewed and approved by an IRB or another ‘local
group’. Some participants felt that donors should be
contacted and new consents obtained for each use,
while others were comfortable with review and ap-
provals for future uses by an individual assigned re-
sponsibility for the management and supervision of the
specimen storage facility. One group agreed that an IRB
could approve future uses but emphasized that the review-
ing IRB should be a national body, such as the HRDC, and
not a local IRB like itself. Those that felt that authority for
approval of future use could be delegated to an IRB or
other body also felt it was imperative that a strong national
regulatory framework be in place so that ‘rules were estab-
lished and clear’.
IRB members who felt that all reuse was contingent
on re-consent by individuals and families from whom
the specimens had been obtained stated that specimens
needed to be kept in identifiable form for this purpose.
Somewhat at odds with this point of view, they were also
part of a majority of participants who expressed the view
that it was important that specimens be stored in de-
identified form for all reuse as a way to ensure privacy.
At the same time, most felt that it was important to be
able to link data back in the event of discoveries that
might be relevant to their health.
There was a fairly lengthy discussion in all groups
about the criteria for reuse. Several participants voiced
the opinion that many Batswana would be opposed to
reuse if the intended uses were not specified. It was felt
that researchers would be seen to be “conniving” if they
request permission to re-use specimens for unspecified
purposes. Those who thought reuse might be acceptable
to research subjects shared a number of different view-
points about the conditions that would apply, including
reuse only within the context of the original study, reuse
for future studies within the same disease category, reuse
during a fixed period of time, and reuse contingent on
approval of donors and/or an IRB.
Several groups raised the topic of priority-setting in the
context of reuse; they expressed concerns that international
researchers might have aims in mind for future use that did
not address local needs in Botswana.
“It should not just be a blanket, open reuse…I
shouldn’t [get] to reuse specimens just because today I
feel like doing research on something that doesn’t
return to the nation or to the community. You
shouldn’t just be doing research because you just want
to learn whatever is happening. There are national
and community interests.”
Ownership and storage
Discussions regarding ownership elicited strong opinions
from all the IRB members. Some members felt that speci-
mens belong to the person who gave them, and that indi-
vidual donors should retain control and access to them,
even in storage, and should be able to retrieve them if they
so choose.
“If I donate a sample for research as a participant,
that sample is mine. That belongs to me…My DNA
and everything is there. That belongs to me… I need
some control or comfort level with my sample.”
Several IRB member participants expressed the minority
opinion that biospecimens should be the property of the
researcher or the research institution to whom they were
originally given. Even though several participants suggested
that there might be gradual transference of ownership
between researcher and the nation, and that specimens
may for a time have to be located outside the country, the
majority of participants agreed that ultimately the speci-
mens should belong to Botswana. The government, they
felt, should be the ultimate gatekeeper.
“I think that if I get specimens for my research, there
should be a point at which they don’t belong to me
anymore, when they ought to belong to the community
of researchers or to the human community. [But] there
should also be regulations at different levels. You
know, if the specimens are here at some stage, they
have to be transferred from me either to the university
or to the country and the country will take custody of
those specimens for future generations and everybody
else.”
The common belief that specimens are “used up” in
an individual’s care was seen by most IRB members as a
major obstacle to acceptance by Batswana of HBS reuse
and storage. One discussant observed “the keeping is the
problem,” conveying in one phrase local concerns that
specimens would not be wholly used for a person’s own
care, that specimens would be “out there somewhere” at
the time of death, and that someone else without the
same obligations to self, community, and country would
control them.
One group voiced distinctly different views about dur-
ation and benefits of storage. This group included the
more ‘seasoned’ IRB members from the HRDC and the
University of Botswana. These participants introduced
some pragmatic considerations not voiced by others.
“My concern is the fact that once specimens have been
collected, at some point, people [will be] required to
destroy them. It’s such a waste, you know…. To say
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after three years, ‘okay, destroy them’ doesn’t seem to
me to be a good solution. It presumes that we are
going to do harm with that specimen [and that] we
[the IRB] are not watching. We just throw away
specimens. One hundred years from now, researchers
would benefit from specimens if they can keep them
that long. But unfortunately we throw them away.”
IRB-member attitudes towards storage were linked to
concerns about access. Many felt that storage of speci-
mens could be of benefit if priority access was given to
local researchers wishing to conduct research of direct
benefit to Botswana. There was general agreement that a
regulatory framework was needed to ensure safeguarding
of specimens regardless of duration of storage.
There was widespread consensus among participants
that, ultimately, specimens should be kept in Botswana.
“I have a problem with the specimens going out. Why?
Because you never know what they are going to be
used for. You have no control over them once they
have left the country. I’d rather prefer whoever wants
to do that research should have a budget that is
enough to bring whatever equipment or facility here
and do whatever he wants to do in the country so we
can benefit.”
Participants acknowledged the need to build capacity
in-country for storage, safekeeping, and research, with
most voicing the view that the international research
community should help in this effort.
Potential benefits and benefit-sharing
Concerns about reuse and storage were generally linked to
considerations about how individuals, communities, and
the nation could benefit. Complicating such discussions
was the conflation of ‘payment’ to research subjects for
their time and inconvenience at point of specimen collec-
tion with ‘benefit’. Because many IRB members viewed this
practice as payment to subjects for the use of their sample
or information, it followed that subjects should continue to
be paid (in their words ‘benefit’) each time their samples
were re-used.
IRB members felt it was important that any benefits
derived from the use of stored specimens, including
monetary gains, intellectual property rights, or new
treatments, should be shared with the individuals who
provided the specimen, their communities, and/or the
nation as a whole. Most participants recognized that this
is already a concern with current single-study use that
would become more pronounced when specimens were
stored and reused, particularly if storage was located
outside of Botswana.
Several participants felt that concerns over benefits were
exacerbated by a general lack of feedback to research sub-
jects about study results, particularly in light of widespread
confusion about ‘research’ versus ‘clinical care’, from which
patients routinely received some benefit, often in the form
of a medication, treatment, or a return to health.
“If they [research subjects] are not given results, it
affects the future and the chances that others will give
specimens. How come you always come to us and
never give us feedback?”
Others remarked on the woeful lack of recognition of
the contribution that research subjects make. Seeing such
recognition as a form of benefit, it was their opinion that
a lack of such acknowledgement had a negative impact on
people’s willingness to participate in research.
“We see nowadays people who have contributed to the
good work, contributed to the research in many
ways….how do we recognize [and] reward the person,
from whose specimens we learned something
important?....Reward does not need to be monetary…
If the people contributed to an achievement in
research, they should be recognized and
acknowledged. If our grandfathers built a school, we
continue to be proud of this school because it wears
our grandfathers’ names.”
Educational needs and regulatory guidance
Study participants were unanimous in their recognition of
the need for more education and training opportunities for
IRB members, particularly on issues relating to genetic and
genome-based research. They agreed that all committee
members must be knowledgeable about issues relating to
biomedical research, research ethics and, in particular, the
use of biospecimens. A number of participants, particularly
those from the newer IRBs, voiced frustration at the lack of
information they had on which to base their deliberations
and the limited recognition that was given to the amount
of time required for review.
“The official training would help. It would be better
than what we are now. We don’t want to be biased.
If we tell someone that they have to comply, we need
to know… For some [IRB members] its core
business, but the rest of us are dragged in. If you
knew this was ‘certified’ business, you would work
more at it.”
“We came here to do other things; we are [co-] opted
to be in the IRB. I don’t even have time to think or
read on my own, or to learn what the expectations are.
And I have to read so many papers.”
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When asked if they were familiar with any regulatory
guidance for research and if so, if they felt it was adequate,
most study participants agreed that such guidance existed,
but were generally not familiar with it or felt that it was
‘easy to bypass’. All but one IRB member believed that
there were existing regulations about biospecimens. Most
participants were familiar with the existence of a forthcom-
ing Health Research Law and expressed general anticipa-
tion that this law would address existing inconsistencies
and concerns with respect to access, ownership, and
storage of biospecimens and benefit-sharing.
It was generally felt that regulations would increase the
consistency of IRB reviews and would reduce the percep-
tion of inconsistent, discretionary decision-making by IRB
members.
“[A national policy] would be very important. See,
right now, either we don’t know things well, or we can
bypass them. If there were clear regulations, we would
be able to prevent people from operating differently.
Tomorrow I am going to be able to say, ‘This is the
law’. A proper legislation, along with penalties and
everything. It will apply to everybody. That would be
better.”
Discussion
A number of the issues raised by study participants echo
findings from other studies in developing countries that
examined community attitudes and norms towards bio-
medical research. Similar concerns about the use of human
‘parts’ for sorcery or witchcraft have previously been
reported in the academic literature as has the attribution of
cultural meaning to parts of the human body [29–33].
Bodily integrity, particularly at death, has been identified
as a critical value in various cultural and religious traditions
and one with significant ramifications for research [34, 35].
To what extent the meaning given to bodily integrity might
cause communities to resist the donation of biospecimens
for future research and storage is new to considerations
about biobanking in Africa and warrants further study,
particularly in the context of genetic and genomic research
involving biosamples in Botswana.
Trust has also been identified elsewhere as central to
the research subject–researcher relationship and in the
willingness of individuals to participate in research [31, 32,
36, 37]. IRB members in Botswana emphasized the
absence of trust as a significant problem, attributing this
in part to lack of understanding on the part of Batswana
and lack of adequate explanation and study feedback on
the part of researchers. This failure to engage with
communities adequately has been cited previously as a
cause for erosion of trust in researchers in developing
countries [38]. De Vries and colleagues observed that trust
between researchers and research subjects may be further
diluted when samples are exported for use by strangers in
foreign countries [10].
IRB-member views that Batswana are likely to be resist-
ant to the reuse of their specimens is in sharp contrast with
earlier findings from Uganda that 95 % of research subjects
interviewed would be comfortable with the reuse of their
biospecimens contingent on IRB review [39]. A recent
study by Igbe and Adebamowo also found that lay persons
in Nigeria, once biobanking was explained to them, felt that
storage and reuse was a ‘worthwhile’ activity [40].
Donor consent or local approval for reuse was preferred
by the majority of IRB members in this study, a point of
view they felt accurately represented how Batswana in gen-
eral would feel and how they themselves felt as members
of the IRB. Most agreed that review and decision-making
could be delegated to a knowledgeable IRB or other regula-
tory body in Botswana. Review and approval by bodies
outside the country was generally not considered adequate
protection for the interests of the individuals and commu-
nities from whom the biospecimens had been collected.
Ownership was a particularly contentious topic in this
study, reflecting a consensus that samples ultimately
belonged to the people of Botswana and by extension
should be under the care and protection of the national
government. Similarly, Moodley and colleagues found that
most of the perspectives voiced by research subjects in
South Africa regarding sample storage, export, reuse, and
benefit-sharing ultimately had to do with ownership [32].
Participants in that study, despite discussions about ‘dona-
tions’, persisted in referring to ‘my blood’ or ‘my child’s
blood’ just as IRB members in this study repeatedly
emphasized “my specimen”, “my samples”, or commented
“if I donate a sample for research as a participant, that
sample is mine”.
The expectation that an individual’s samples will be
used up in the course of his or her own care may be
viewed by Batswana as a fair exchange — the ‘giving up’
of a specimen in exchange for treatment or return to
health — that is absent when they are asked to provide a
specimen for the purposes of research. Certainly there is
concern among IRB members that societal benefits may
be absent if specimens are taken outside the country or
if decisions as to their future use do not remain in the
hands of the donors themselves or the government of
Botswana. IRB members in Botswana discussed benefits
both in very basic terms of compensation to research
subjects themselves and in broader language suggesting
that they view biosamples as a collective resource that
should be used primarily for the benefit of the country
and all its citizens.
Familiarity with pharmacogenetics and genomic research
was limited in IRB members participating in this study.
Participants on the two most active IRBs – the national
HRDC and the IRB at the University of Botswana – were
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more comfortable discussing the scientific aspects of
research and more likely to consider the potential benefits
of genetic- and genomic-based research than their coun-
terparts in the newer and less active IRBs. There was a
uniform call from all IRB members for more training in
these areas, a need that has been expressed by similar
constituencies in other African countries [41–44].
Uniformly absent from the discussions in all groups, re-
gardless of their familiarity with research or their experi-
ence as IRB members, were several topics of particular
relevance to biomedical research in Botswana. First, the
concept of ‘benefit’ was narrowly viewed by IRB members
only within the context of individual, community, and na-
tional interests of Botswana. Little, if any, consideration was
given to the potential benefits that genetic- and genomic-
based research using biospecimens from Botswana could
offer other peoples in Africa or other populations world-
wide sharing common traits, risk-profiles or diseases des-
pite follow-on questions on this issue from the study team.
This consideration of benefit only within the geographic
boundaries of their country may simply reflect what IRB
member participants perceived as the ‘local’ focus of this
current study. However, if the discussants’ comments are
symptomatic of a broader territorial protectionism, it sug-
gests that there may be some resistance to proposals that
call for export of biospecimens to regional or non-African
biorepositories located outside of Botswana. Concerns such
as these, for example, have been noted previously in South
Africa [45]. In particular, it may reflect a negative view of
management and reuse of such specimens by foreign inves-
tigators without local oversight. Such attitudes could be
directly at odds with the ‘common heritage’ approach
that underpins many international and regional strat-
egies for biobanking, including the current H3Africa
initiatives [7, 46].
Second, despite the near unanimity of IRB members as to
the lack of understanding on the part of research subjects
in Botswana and the particularly disturbing reports that
participants are frequently unaware that they are subjects
of research or that their specimens are not exhausted in
their own care, the IRB members participating in this study
did not evidence any sense of personal responsibility as
‘gatekeepers’ to address such concerns. Despite the national
mandate to its IRBs to “ensure that the dignity, rights,
safety and well-being of research subjects are protected”
[27], and the IRB members’ uniform call for more ethics
training, there was little evidence that the IRB members at
present saw their boards accountable for the remediation of
ethical ‘gaps’ in how studies are actually taking place on the
ground. Training requirements for new IRB members,
combined with continuing professional development op-
portunities for current members, can certainly help. The
success of such efforts, however, will depend on the exist-
ence of clear regulatory guidance as well as adequate
investment in research governance and support structures.
All IRB members need to be given access to training, time-
off from other responsibilities, and recognition for the value
of their service if they are to function as effective, meaning-
ful stewards of citizen safety, rights, and dignity in research.
Limitations of this study
The authors chose to study the perspectives of IRB mem-
bers in Botswana in order to understand the challenges
they face as ethical gatekeepers responsible for the review
of increasingly sophisticated research involving the collec-
tion, use, and storage of HBS, and to assess the need from
by IRB members for specialized training in this domain. To
that end, the study provides insights through their eyes only
on community knowledge, attitudes, and beliefs about bios-
pecimens. To address this limitation, more studies are
needed in Botswana that directly engage local communities
in order to appreciate what is likely to be the broad range
of understanding and opinion on ethical, legal, and social
implications associated with biospecimens, particularly
those collected as part of research biorepositories. The need
for such discussions have been recently highlighted by the
H3Africa Working Group on Ethics [47]. At the same time,
opportunities for more in-depth debate among IRB mem-
bers in Botswana regarding areas of concern to the
constituencies they protect would help to tailor both fu-
ture IRB-member training and public health outreach.
Information provided through studies involving other
non-Botswana populations as well as international guid-
ance on ethical concerns at the community-level in devel-
oping countries offer some help in navigating the terrain
but are not sufficient to fully understand local complex-
ities nor identify points of opportunity for education,
participation, and collaboration that are most appropriate
for Botswana.
Conclusion
A number of IRB-member concerns identified in this
study may well be addressed through education and
capacity-building efforts. Greater investment on the part
of the Botswana health system as well as the international
research community in community-level education could
reduce misconceptions about how biospecimens are used,
sharpen the distinction in patient understanding between
clinical care and medical research, and engender a greater
appreciation for the potential benefits afforded their
communities by new advances in research. Opportunities
for community engagement, both pre- and post-research,
should be addressed in all study protocols, with clearly ar-
ticulated plans for community feedback. Future education
and training activities for IRB members can address the
current knowledge gap on genetic- and genomic-based
research, the risks and benefits of specimen reuse, regional
biobanks, shared bioinformatics, and the current
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regulatory guidance for review of related protocols.
Capacity-building programs are needed to develop local
expertise in Botswana’s own growing research community
and to create the necessary physical and professional infra-
structure to manage the safe and ethical collection,
utilization, and storage of biospecimens. Once developed
and enacted, clear national policy on the export, ownership,
and terms of use for biospecimens in research can provide
a guide for research priority-setting, partnerships, review,
and oversight.
This study also identified some areas that may prove less
malleable to change. These include indigenous meanings
ascribed to the human body and its parts that seem to be
at odds with ‘western’ scientific knowledge and practice.
Engagement by the international research community
with local stakeholders will be needed to harmonize these
fundamentally different ways of understanding the human
body and community identity with the aims of contem-
porary biomedicine.
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